Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | RECQL | P46063 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5567058 | 0.95 | SMN1; SMN2 (0.63) | SMN1; SMN2KDM4ERECQLALDH1A1TSHR | |
| SCHEMBL2547923 | 0.84 | SMN1; SMN2 (0.51) | SMN1; SMN2KDM4ERECQLALDH1A1TSHR | |
| SCHEMBL5452364 | 0.80 | SMN1; SMN2 (0.75) | SMN1; SMN2KDM4ERECQLALDH1A1TSHR | |
| SCHEMBL3013547 | 0.80 | MAPK1 (0.90) | SMN1; SMN2KDM4ERECQLALDH1A1TSHR | |
| SCHEMBL28111321 | 0.80 | SMN1; SMN2 (0.75) | SMN1; SMN2KDM4ERECQLALDH1A1TSHR | |
| SCHEMBL13297951 | 0.80 | ALDH1A1 (0.90) | SMN1; SMN2KDM4ERECQLALDH1A1TSHR | |
| SCHEMBL4024058 | 0.80 | SMN1; SMN2 (0.75) | SMN1; SMN2KDM4ERECQLALDH1A1TSHR | |
| SCHEMBL14842266 | 0.80 | SMN1; SMN2 (0.75) | SMN1; SMN2KDM4ERECQLALDH1A1TSHR | |
| SCHEMBL4041413 | 0.79 | KDM4E (0.74) | SMN1; SMN2KDM4ERECQLALDH1A1TSHR | |
| SCHEMBL27743682 | 0.79 | SMN1; SMN2 (0.67) | SMN1; SMN2KDM4ERECQLALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3759075-B1 | COMPOUNDS WITH FERROPTOSIS INDUCING ACTIVITY AND METHODS OF THEIR USE | FERRO THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20230039846-A1 | COMPOUNDS AND METHODS OF USE | FERRO THERAPEUTICS INC (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230039846-A1 | COMPOUNDS AND METHODS OF USE | FERRO THERAPEUTICS INC (US) | 2023-02-09 | — | — | US | disclosed |
| EP-3759075-A1 | COMPOUNDS WITH FERROPTOSIS INDUCING ACTIVITY AND METHODS OF THEIR USE | Ferro Therapeutics, Inc. (US) | 2021-01-06 | — | — | EP | disclosed |
| CN-112041301-A | Compounds having iron death inducing activity and methods of use thereof | 费罗治疗公司 | 2020-12-04 | — | — | CN | disclosed |
| US-20190263802-A1 | COMPOUNDS AND METHOD OF USE | MOLECULAR SKIN THERAPEUTICS, INC. | 2019-08-29 | — | — | US | disclosed |
| US-20190263802-A1 | COMPOUNDS AND METHOD OF USE | MOLECULAR SKIN THERAPEUTICS, INC. | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039846-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, GPX4, GPX1 | SMN1; SMN2 2416/4885KDM4E 2312/4885RECQL 2822/4885 |
| US-20190263802-A1 | COMPOUNDS AND METHOD OF USE | AIFM2, GPX4, GPX1 | SMN1; SMN2 2428/4885KDM4E 2426/4885RECQL 3729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.